{"id":540748,"date":"2021-09-21T17:18:01","date_gmt":"2021-09-21T21:18:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\/"},"modified":"2021-09-21T17:18:01","modified_gmt":"2021-09-21T21:18:01","slug":"graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\/","title":{"rendered":"Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BALTIMORE, Sept.  21, 2021  (GLOBE NEWSWIRE) &#8212; Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 11:20 a.m. ET \/ 8:20 a.m. PT. Dr. Guerard will provide a corporate update, including a full analysis of the 18-month data from the ALTISSIMO Phase 2b trial of GB-102 1mg.\u00a0\u00a0<\/p>\n<p>A live webcast of the presentation will be available in the Investors and Media section of the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ULFnne5UmM3L6iVrJ0ywYQgVzDMnqn9eZdlcG_CBh8TV8jCE1o5-grTPOd_e6zzL2yqDfJJIyGMIB1hSOL_BTaUjh6ADfygcNox_LkAVdcpI1rZ61kDyBNPEhLRZctXiuWNtq7wWaZ3UIwzs-_nFOTpfzoH3J0F4SvsCyHA9C_YhtuSBiW_LbWbGBuAref7gS5aqnTkyx8NEY0aEHGhNzg==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/investors.graybug.vision\/news-events\/events-presentations<\/a>, with a replay available shortly after the live event.\u00a0\u00a0<\/p>\n<p>\n        <strong>About Graybug<\/strong>\n      <\/p>\n<p>Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The company\u2019s proprietary ocular delivery technologies are designed to maintain effective drug levels in ocular tissue for six months and potentially longer, improving disease management, reducing healthcare burdens and ultimately delivering better clinical outcomes. Graybug\u2019s lead product candidate, GB-102, a formulation of the pan-vascular endothelial growth factor (VEGF) inhibitor, sunitinib malate targeting a six-month or longer dosing regimen, inhibits multiple neovascular pathways for the intravitreal treatment of retinal diseases, including wet age-related macular degeneration. Graybug\u2019s other product candidates developed using its proprietary technologies also include GB-401, an injectable sustained-release formulation of a beta-adrenergic blocker prodrug, for primary open-angle glaucoma, with a dosing regimen of once every six months or longer, and GB-103, a longer-acting version of GB-102, designed to maintain therapeutic drug levels in the retinal tissue for 12 months with a single injection. Founded in 2011 on the basis of technology licensed from the Johns Hopkins University School of Medicine, Graybug is headquartered in Baltimore, Maryland. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TGWdnk79TumBnmFfl4yBAAnSEGaSjpVZqVGCKQWo6TRVd6uzikckK9Jc-vjQBsKv0OOHWDODIYMjJpcbw0oRUGIxM2U8hy8HoKRs_GqvT6g=\" rel=\"nofollow noopener\" target=\"_blank\">www.graybug.vision<\/a>.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Investor Contact<\/strong><br \/>\n            <br \/>\n            <a href=\"mailto:IR@graybug.vision\" rel=\"nofollow noopener\" target=\"_blank\">IR@graybug.vision<\/a><br \/>\n            <br \/>(650) 487-2409<\/p>\n<\/td>\n<td style=\"vertical-align: top\">\n            <strong>Media Contact<\/strong><br \/>\n            <br \/>\n            <a href=\"mailto:media@graybug.vision\" rel=\"nofollow noopener\" target=\"_blank\">media@graybug.vision<\/a><br \/>\n            <br \/>(404) 384-0067<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMzMDAyMyM0NDE3MDM1IzIwOTQxMDQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MjY4NTk3ZTItNTk3Ni00ZWFjLTg0YTgtN2Q5YTViMDgzNDI4LTExMDU2NzU=\/tiny\/Graybug-Vision-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BALTIMORE, Sept. 21, 2021 (GLOBE NEWSWIRE) &#8212; Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 11:20 a.m. ET \/ 8:20 a.m. PT. Dr. Guerard will provide a corporate update, including a full analysis of the 18-month data from the ALTISSIMO Phase 2b trial of GB-102 1mg.\u00a0\u00a0 A live webcast of the presentation will be available in the Investors and Media section of the company\u2019s website at https:\/\/investors.graybug.vision\/news-events\/events-presentations, with a replay available shortly after the live &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-540748","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BALTIMORE, Sept. 21, 2021 (GLOBE NEWSWIRE) &#8212; Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 11:20 a.m. ET \/ 8:20 a.m. PT. Dr. Guerard will provide a corporate update, including a full analysis of the 18-month data from the ALTISSIMO Phase 2b trial of GB-102 1mg.\u00a0\u00a0 A live webcast of the presentation will be available in the Investors and Media section of the company\u2019s website at https:\/\/investors.graybug.vision\/news-events\/events-presentations, with a replay available shortly after the live &hellip; Continue reading &quot;Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-21T21:18:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMzMDAyMyM0NDE3MDM1IzIwOTQxMDQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference\",\"datePublished\":\"2021-09-21T21:18:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\\\/\"},\"wordCount\":334,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMzMDAyMyM0NDE3MDM1IzIwOTQxMDQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\\\/\",\"name\":\"Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMzMDAyMyM0NDE3MDM1IzIwOTQxMDQ=\",\"datePublished\":\"2021-09-21T21:18:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMzMDAyMyM0NDE3MDM1IzIwOTQxMDQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMzMDAyMyM0NDE3MDM1IzIwOTQxMDQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference - Market Newsdesk","og_description":"BALTIMORE, Sept. 21, 2021 (GLOBE NEWSWIRE) &#8212; Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 11:20 a.m. ET \/ 8:20 a.m. PT. Dr. Guerard will provide a corporate update, including a full analysis of the 18-month data from the ALTISSIMO Phase 2b trial of GB-102 1mg.\u00a0\u00a0 A live webcast of the presentation will be available in the Investors and Media section of the company\u2019s website at https:\/\/investors.graybug.vision\/news-events\/events-presentations, with a replay available shortly after the live &hellip; Continue reading \"Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-21T21:18:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMzMDAyMyM0NDE3MDM1IzIwOTQxMDQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference","datePublished":"2021-09-21T21:18:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\/"},"wordCount":334,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMzMDAyMyM0NDE3MDM1IzIwOTQxMDQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\/","name":"Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMzMDAyMyM0NDE3MDM1IzIwOTQxMDQ=","datePublished":"2021-09-21T21:18:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMzMDAyMyM0NDE3MDM1IzIwOTQxMDQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMzMDAyMyM0NDE3MDM1IzIwOTQxMDQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graybug-vision-to-participate-in-the-cantor-virtual-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/540748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=540748"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/540748\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=540748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=540748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=540748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}